SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Pharmova - Quaterly Results

27 May 2022 Evaluate
The Sales for the quarter ended March 2022 of Rs. 287.90 million declined by -92.13% from Rs. 3658.60 millions.The Net Loss for the quarter ended March 2022 is Rs. -31.10 millions as compared to Net Profit of Rs. 351.60 millions of corresponding quarter ended March 2021Operating Profit reported a sharp decline to 55.10 millions from 689.70 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 287.90 3658.60 -92.13 877.50 27095.00 -96.76 877.50 27095.00 -96.76
Other Income 71.00 138.00 -48.55 1258.70 478.80 162.89 1258.70 478.80 162.89
PBIDT 55.10 689.70 -92.01 1190.90 4749.40 -74.93 1190.90 4749.40 -74.93
Interest 80.60 121.00 -33.39 305.90 1018.00 -69.95 305.90 1018.00 -69.95
PBDT -25.50 568.70 -104.48 885.00 3731.40 -76.28 885.00 3731.40 -76.28
Depreciation 15.90 110.00 -85.55 62.50 999.70 -93.75 62.50 999.70 -93.75
PBT -41.40 458.70 -109.03 822.50 2731.70 -69.89 822.50 2731.70 -69.89
TAX -10.30 107.10 -109.62 37.50 586.90 -93.61 37.50 586.90 -93.61
Deferred Tax -4.00 47.30 -108.46 -99.10 132.50 -174.79 -99.10 132.50 -174.79
PAT -31.10 351.60 -108.85 785.00 2144.80 -63.40 785.00 2144.80 -63.40
Equity 159.30 159.30 0.00 159.30 159.30 0.00 159.30 159.30 0.00
PBIDTM(%) 19.14 18.85 1.52 135.72 17.53 674.25 135.72 17.53 674.25

Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×